{"title":"National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.","authors":"Maryam Sadat Mirenayat, Atefeh Abedini, Arda Kiani, Alireza Eslaminejad, Parisa Adimi Naghan, Majid Malekmohammad, Jalal Heshmatnia, Seyed Alireza Nadji, Esmaeil Idani, Reyhaneh Zahiri, Somayeh Lookzadeh, Hakimeh Sheikhzade, Farzaneh Dastan, Mihan Porabdollah Toutkaboni, Mitra Sadat Rezaei, Elham Askari, Payam Tabarsi, Majid Marjani, Afshin Moniri, Seyed Mohammad Reza Hashemian, Behrooz Farzanegan, Zahra Abtahian, Fatemeh Yassari, Nazanin Mansouri, Davood Mansouri, Maryam Vasheghani, Babak Mansourafshar, Mojtaba Mokhber Dezfoli, Salman Soleimani, Sharareh Seifi, Farah Naghashzadeh, Atefeh Fakharian, Mohammad Varahram, Hamidreza Jamaati, Alireza Zali, Ali Akbar Velayati","doi":"10.5812/ijpr.123947","DOIUrl":null,"url":null,"abstract":"<p><p>More than a year after the onset of the coronavirus disease pandemic in 2019, the disease remains a major global health issue. During this time, health organizations worldwide have tried to provide integrated treatment guidelines to control coronavirus disease 2019 (COVID-19) at different levels. However, due to the novel nature of the disease and the emergence of new variants, medical teams' updating medical information and drug prescribing guidelines should be given special attention. This version is an updated instruction of the National Research Institute of Tuberculosis and Lung Disease (NRITLD) in collaboration with a group of specialists from Masih Daneshvari Hospital in Tehran, Iran, which is provided to update the information of caring clinicians for the treatment and care of COVID-19 hospitalized patients.</p>","PeriodicalId":416671,"journal":{"name":"Iranian Journal of Pharmaceutical Research : IJPR","volume":" ","pages":"e123947"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/08/ijpr-21-1-123947.PMC9191225.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research : IJPR","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijpr.123947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
More than a year after the onset of the coronavirus disease pandemic in 2019, the disease remains a major global health issue. During this time, health organizations worldwide have tried to provide integrated treatment guidelines to control coronavirus disease 2019 (COVID-19) at different levels. However, due to the novel nature of the disease and the emergence of new variants, medical teams' updating medical information and drug prescribing guidelines should be given special attention. This version is an updated instruction of the National Research Institute of Tuberculosis and Lung Disease (NRITLD) in collaboration with a group of specialists from Masih Daneshvari Hospital in Tehran, Iran, which is provided to update the information of caring clinicians for the treatment and care of COVID-19 hospitalized patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
